American Journal of Ophthalmology
Volume 145, Issue 6 , Pages 951-958.e1 , June 2008

Ocular TRUST: Nationwide Antimicrobial Susceptibility Patterns in Ocular Isolates

  • Penny A. Asbell

      Affiliations

    • Mount Sinai School of Medicine, New York, New York
    • Corresponding Author InformationInquiries to Penny A. Asbell, Department of Ophthalmology, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, Box 1183, New York, NY 10029
    • ,
  • Kathryn A. Colby

      Affiliations

    • Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts
    • ,
  • Sophie Deng

      Affiliations

    • Jules Stein Eye Institute, Los Angeles, California
    • ,
  • Peter McDonnell

      Affiliations

    • Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, Maryland
    • ,
  • David M. Meisler

      Affiliations

    • Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio
    • ,
  • Michael B. Raizman

      Affiliations

    • New England Eye Center, Tufts University School of Medicine and Ophthalmic Consultants of Boston, Boston, Massachusetts
    • ,
  • John D. Sheppard Jr

      Affiliations

    • Virginia Eye Consultants, Norfolk, Virginia
    • ,
  • Daniel F. Sahm

      Affiliations

    • Eurofins Medinet, Inc, Anti-Infective Services, Herndon, Virginia.

,Accepted 11 January 2008.

References 

  1. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology. 1999;106:1313–1318
  2. Thornsberry C, Jones ME, Hickey ML, Mauritz Y, Kahn J, Sahm D. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolated in the United States, 1997–1998. J Antimicrob Chemother. 1999;44:749–759
  3. Thornsberry C, Sahm DF, Kelly LJ, et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999–2000. Clin Infect Dis. 2002;34:S4–S16
  4. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically (Approved standard). 7th ed. Wayne, Pennsylvania: Clinical and Laboratory Standards Institute (CLSI); 2006;(M7-A7)
  5. Drug Topics (Top 200 brand-name/generic drugs by units in 2006). http://drugtopics.com/drugtopics/data/articles/drugtopics/092007/407652/article.pdfAccessed: April 20, 2007
  6. Sahm DF, Marsillo MK, Piazza G. Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the Surveillance Network Database-USA. Clin Infect Dis. 1999;29:259–263
  7. Critchley IA, Blosser-Middleton RS, Jones ME, Thornsberry C, Sahm DF, Karlowsky JA. Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000–2001. Antimicrob Agents Chemother. 2003;47:1689–1693
  8. Kaka AS, Rueda AM, Shelburne SA, Hulten K, Hamill RJ, Musher DM. Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2006;58:680–683
  9. Sabol KE, Echevarria KL, Lewis JS. Community-associated methicillin-resistant Staphylococcus aureus: new bug, old drugs. Ann Pharmacother. 2006;40:1125–1133
  10. Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis. 2001;7:337–341
  11. Fukuda H, Kishii R, Takei M, Hosaka M. Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae. Antimicrob Agents Chemother. 2001;45:1649–1653
  12. Fukuda H, Hiramatsu K. Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother. 1999;43:410–412
  13. Pestova E, Millichap JJ, Noskin G, Peterson LR. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. J Antimicrob Chemother. 2000;45:583–590
  14. Yague G, Morris JE, Pan X, Gould KA, Fisher LM. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones. Antimicrob Agents Chemother. 2002;46:413–419
  15. Beyer R, Pestova E, Millichap JJ, Stosor V, Noskin GA, Peterson LR. A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux. Antimicrob Agents Chemother. 2000;44:798–801
  16. Broskey J, Coleman K, Gwynn MN, et al. Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae. J Antimicrob Chemother. 2000;45:S95–S99
  17. Robertson SM, Curtis MA, Schlech BA, et al. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. Surv Ophthalmol. 2005;50:S32–S45
  18. Kowalski RP, Dhaliwal DK, Karenchak LM, et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol. 2003;136:500–505
  19. Rhee MK, Kowalski RP, Romanowski EG, Mah FS, Ritterband DC, Gordon YJ. A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa. Am J Ophthalmol. 2004;138:226–230
  20. Mather R, Karenchak LM, Romanowski EG, Kowalski RP. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol. 2002;133:463–466
  21. Kowalski RP, Deepinder DK. Ocular bacterial infections: current and future treatment options. Expert Rev Anti Infect Ther. 2005;3:131–139
  22. Alexandrakis G, Alfonso EC, Miller D. Shifting trends in bacterial keratitis is South Florida and emerging resistance to fluoroquinolones. Ophthalmology. 2000;107:1497–1502
  23. Miller D, Alfonso EC. Comparative in vitro activity of levofloxacin, ofloxacin, and ciprofloxacin against ocular streptococcal isolates. Cornea. 2004;23:289–293
  24. Miller D, Flynn PM, Scott I, Alfonso EC, Flynn HW. In vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolates. Arch Ophthalmol. 2006;124:479–483
  25. Marangon FB, Miller D, Muallem M, Romano AC, Alfonso EC. Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis. Am J Ophthalmol. 2004;137:453–458
  26. Sahm DF, Karlowsky JA, Kelly LJ, et al. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis. Antimicrob Agents Chemother. 2001;45:1037–1042
  27. Critchley IA, Karlowsky JA. Optimal use of antibiotic resistance surveillance systems. Clin Microbiol Infect. 2004;10:502–511
  28. Raizman MB, Rubin JM, Graves AL, Rinehart M. Tear concentrations of levofloxacin following topical administration of a single dose of 0.5% levofloxacin ophthalmic solution in healthy volunteers. Clin Ther. 2002;24:1439–1450
  29. Ortho-McNeil Pharmaceutical, Inc. Levaquin (levofloxacin) prescribing information. Raritan, New Jersey: Ortho-McNeil Pharmaceutical, Inc; 2004;

PII: S0002-9394(08)00087-1

doi: 10.1016/j.ajo.2008.01.025

American Journal of Ophthalmology
Volume 145, Issue 6 , Pages 951-958.e1 , June 2008

Article Tools

* Image Usage & Resolution